Overview

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

Status:
Recruiting

Trial end date:
2022-07-22

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of AZD9977 alone and AZD9977 in combination with dapagliflozin and to assess the dose-response relationship of placebo, AZD9977 alone, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 55%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between 20 and 60 mL/min/1.73 m^2, with at least 30% of participants with eGFR ≥ 20 to <30 mL/min/1.73^2 and a maximum of 25% of participants with eGFR >45 mL/min/1.73 m^2]), including at least 40% of participants with type 2 diabetes mellitus (T2DM).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin